Recursion Pharmaceuticals May Be Losing Ground To Its Peers
Source: SeekingAlpha
2026-04-27 20:16:55 ET
Recursion Pharmaceuticals, Inc. ( RXRX ) describes itself as a "clinical-stage TechBio company decoding biology to radically improve lives." The company’s vision is based on the premise that most diseases – they estimate around 80% – still lack disease-modifying therapies, and that AI can be harnessed in the drug discovery phase to expedite the process of identifying potential therapies....
Read the full article on Seeking Alpha
For further details see:
Recursion Pharmaceuticals May Be Losing Ground To Its Peers
Absci Corporation
NASDAQ: ABSI
ABSI Trading
22.16% G/L:
$7.085 Last:
5,240,234 Volume:
$5.99 Open:
ABSI Latest News
May 07, 2026 04:05:00 pm
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
April 23, 2026 04:05:00 pm
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
ABSI Stock Data
$396,980,842
134,597,557
0.04%
50
N/A
Biotechnology & Life Sciences
Healthcare
US
Vancouver
